awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q27853167-601CFD21-2927-4B49-BD2B-FFFFF9CCD332
Q27853167-601CFD21-2927-4B49-BD2B-FFFFF9CCD332
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853167-601CFD21-2927-4B49-BD2B-FFFFF9CCD332
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping
P2860
Q27853167-601CFD21-2927-4B49-BD2B-FFFFF9CCD332
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853167-601CFD21-2927-4B49-BD2B-FFFFF9CCD332
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fef52b852262548ed587f818808906135d82df22
P2860
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.